Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Aulos Bioscience Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to a single examiner, GODDARD, LAURA B. This concentration suggests that the company's current patent applications are closely related in subject matter, falling under the purview of a single specialist.
The company's prosecution is highly consolidated, featuring 1 distinct examiner and 1 distinct art unit. GODDARD, LAURA B is the busiest examiner, managing 2 pending office actions. Having a single examiner handle the entire pending portfolio can lead to more predictable prosecution, as the applicant only needs to navigate a single individual's interpretation of the prior art.
Because a distinct examiner is handling all pending office actions, the company may experience consistent feedback across its filings. This concentration in a distinct art unit simplifies the administrative oversight of the pending portfolio and allows for a unified strategy. Practitioners should focus on building a consistent dialogue with this examiner to efficiently resolve the pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GODDARD, LAURA B | 2 | 50.8% | +13.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431983 | METHODS OF USE OF ANTI-IL-2 ANTIBODIES | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18431983 | METHODS OF USE OF ANTI-IL-2 ANTIBODIES | GODDARD, LAURA B | — |
| 18404093 | METHODS OF USE OF ANTI-IL-2 ANTIBODIES | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18431983 | METHODS OF USE OF ANTI-IL-2 ANTIBODIES | GODDARD, LAURA B | 1642 | §103§112Other | Non-Final OA | — | Pending | Feb 04, 2024 |
| 18404093 | METHODS OF USE OF ANTI-IL-2 ANTIBODIES | GODDARD, LAURA B | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAulos Bioscience Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Laura B Goddard has the most, with 2 of Aulos Bioscience Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
